Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Net Income-$19.1M
EPS$-0.67
Market Cap$983.7M
Price Performance
Historical data including institutional events
Company Profile
H
Heather Turner
CEO & Executive Director
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation.
The company was incorporated in 2015 and is headquartered in New York, New York.
